It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
Biointelect is a strategic planning and commercialisation firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations.
Biointelect helps its clients develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. The strategy consulting involves therapeutic development from start up through to post launch, with an Australian and a Global perspective.
Biointelect’s mission is to bring science to market.
Biocelect works with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market.
In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand.
Biocelect’s mission is to build pathways to patients.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
You Might also like
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
-
Tasmanian researchers and clinicians working together
Tasmanian medical research charity funds projects that have a global impact and improve community health and well-being.
Australian Health Journal spoke to Stephanie Furler the Chief Executive Officer of The Royal Hobart Hospital Research Foundation about the impact of this research locally and in global health.
-
Clinical research integrates with GP and Pharmacist workflows to supplement practice revenue
Clinical trials are crucial to the development of evidence-based preventative medicines. In addition, participation in clinical trials can also provide patients with opportunities to access new treatments.
“Clinical trials are at the heart of medical advances which look into new ways to treat, prevent, or detect disease. Volunteers often do so to help contribute to advancing scientific research, knowing that they are participating in the hope of helping future generations,” said Charlotte Bradshaw, CEO and Founder to Evrima Technologies.